#### **1** Production of anti-spike antibodies in response to COVID vaccine in lymphoma patients

- 2 Short title: Antibody response to COVID vaccine in lymphoma patients
- 3 Alexandra Della Pia,<sup>1,2</sup> Gee Youn (Geeny) Kim,<sup>1,2</sup> Andrew Ip,<sup>1,4,8</sup> Jaeil Ahn,<sup>3</sup> Yanzhi Liu,<sup>3</sup> Simone Kats,<sup>4</sup> Michael
- 4 Koropsak,<sup>1,4</sup> Brittany Lukasik,<sup>1</sup> Anamta Contractor,<sup>5</sup> Krushna Amin,<sup>6</sup> Lakshmi Ayyagari,<sup>7</sup> Charles Zhao,<sup>8&</sup> Amolika
- 5 Gupta,<sup>8&</sup> Mark Batistick,<sup>8&</sup> Lori A. Leslie,<sup>1,4,8</sup> Andre Goy,<sup>1,4,8</sup> Tatyana Feldman<sup>1,4,8</sup>
- 6

- 8 <sup>2</sup>Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ
- 9 <sup>3</sup>Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC
- 10 <sup>4</sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
- 11 <sup>5</sup>St. George's University School of Medicine, Grenada, West Indies
- 12 <sup>6</sup>Robert Wood Johnson University Hospital, New Brunswick, NJ
- 13 <sup>7</sup>Englewood Health, Englewood, NJ
- 14 <sup>8</sup>Hackensack Meridian School of Medicine, Nutley, NJ
- 15
- 16
- 17 \*Corresponding author: <u>Andrew.ip@hmhn.org</u>18
- 19 <sup>¶</sup>These authors contributed equally to this work.
- 20 <sup>&</sup>These authors also contributed equally to this work.
- 21
- 22
- 23 24
- 25
- 26
- 27

28 29

- 20
- 30 31
- 32
- . .
- 33
- 34
- 35
- 36
- 37
- 38

## 39 Abstract

40 Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an 41 antibody response after COVID infection. There is limited data on the efficacy of the COVID vaccines in lymphoma 42 patients, and to suggest the optimal timing of vaccination to elicit immunity in patients receiving 43 immunochemotherapy. This is a retrospective study of adult lymphoma patients who received the COVID vaccine 44 between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody titer 45 following the primary COVID vaccination series. The primary series was defined as 2 doses of the COVID mRNA 46 vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher's exact test, and 47 unadjusted and adjusted logistic regression models were used for univariate (UVA) and multivariate (MVA) 48 analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 49 patients (23%) with Burkitt's, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma 50 (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); 51 and 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined. One-hundred fifty-eight patients 52 (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. 53 Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-54 COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a 55 numerically lower seroconversion rate of 51% following the primary series whereas patients with HL/TCL appeared 56 to have a robust antibody response with a seropositivity rate of 77% (p=0.04). Lymphoma patients are capable of 57 mounting a humoral response to the COVID mRNA vaccines. Further studies are required to confirm our findings, 58 including whether T-cell immunity would be of clinical relevance in this patient population. 59 60 61 62

- 63
- 64

## 65 Introduction

66 Patients with hematologic malignancies have poor outcomes from COVID infection with associated mortality of up 67 to 30-40%. Studies have shown that these patients are less likely to mount an antibody response after COVID 68 infection [1]. The Pfizer-BioNTech and Moderna COVID mRNA vaccines have been shown to be 94% effective in 69 preventing severe disease in the general population [2]. However, it is well known that certain clinically vulnerable 70 populations do not develop protective immunity after completing the COVID vaccine series [3]. 71 72 Production of antibodies against the SARS-CoV-2 spike protein is the major mechanism of protective immunity 73 induced by COVID vaccination. Patients with lymphoma may be unable to seroconvert following vaccination due to 74 impaired humoral and T-cell immunity secondary to the malignancy itself as well as immunosuppressive treatment 75 [4]. This inability to produce antibodies against the SARS-CoV-2 spike protein is most notable in patients with B-cell 76 lymphomas and chronic lymphocytic leukemia (CLL), with seroconversion rates ranging between 64% to 78% [5]. 77 Treatment with B-cell directed therapies, such as anti-CD20 monoclonal antibodies and Bruton's tyrosine kinase 78 (BTK) inhibitors, further compromises the ability of patients with lymphoma to mount an antibody response 79 following vaccination and persists over time [6]. Vaccine responses in patients with different lymphoma subtypes 80 or receiving B-cell depleting therapies have not been fully elucidated. 81 82 With the emergence of the omicron variant and availability of an additional primary shot of the COVID vaccine, it 83 has become increasingly important to describe the efficacy of the COVID vaccines in lymphoma patients and to 84 suggest the optimal timing of vaccination to elicit immunity in patients receiving immunochemotherapy. There 85 have been several reports of patients with lymphoma frequently not achieving serologic response to COVID 86 vaccines, especially after recent treatments with B-cell directed therapies [6,7]. In this study, we evaluated 87 antibody levels against the SARS-CoV-2 spike protein in lymphoma patients following receipt of the primary COVID 88 vaccination series and additional primary shot. We hypothesized that patients with lymphoma are not developing 89 a robust immune response following vaccination.

## 91 Methods

#### 92 Study Design and Cohort Selection

93 This was a retrospective, single center study at the John Theurer Cancer Center (JTCC) within Hackensack Meridian 94 Health (HMH). Electronic health record (EHR)-derived data was utilized to identify patients who received at least 2 95 doses of the COVID mRNA vaccines or at least 1 dose of the COVID adenovirus vaccine. The primary objective was 96 to evaluate the efficacy of the COVID vaccines following 2 doses of the COVID mRNA vaccines or 1 dose of the 97 COVID adenovirus vaccine. 98 99 Patients were included in this analysis if they were: 1) Adult patients ≥18 years; 2) Had a diagnosis of lymphoma or 100 CLL; 3) Received the COVID vaccine series between December 15, 2020 and November 30, 2021; 4) had a resulted 101 anti-COVID spike protein antibody titer following 2 doses of the COVID mRNA vaccines (Pfizer-BioNTech vaccine 102 and/or Moderna COVID mRNA vaccine) or after 1 dose of the COVID adenovirus vaccine (Johnson&Johnson). 103 104 Institutional Review Board (IRB) approval was obtained. The requirement for patient informed consent was waived 105 by the IRB as this project represented a non-interventional study utilizing routinely collected data for secondary 106 research purposes. 107

#### 108 Data Sources

109 Data was collected from HMH's EHR (Epic) which is utilized throughout the network. Patients treated at JTCC were

110 identified by convenience sampling if they shared their vaccination status at the time of their outpatient visit.

111 Demographics, clinical characteristics, treatments, and outcomes were manually extracted by physicians,

112 pharmacists, nurses, and medical students from JTCC and HMH. Data abstracted by the team was entered into an

113 Excel spreadsheet, and quality control was performed by physicians overseeing data collection.

115 Demographic data included age, sex, race/ethnicity, co-morbidities, and last anticancer treatment received. Co-116 morbidities were defined as any of the following present prior to receipt of the COVID vaccine series: chronic 117 obstructive pulmonary disorder (COPD), autoimmune diseases, liver disease, diabetes mellitus, chronic kidney 118 disease (CKD), human immunodeficiency virus (HIV), cardiovascular disease, and smoking history. Lymphoma types 119 were categorized as follows: chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL); Burkitt's 120 lymphoma/diffuse large B-cell lymphoma (DLBCL)/primary mediastinal B-cell lymphoma (PMBL); indolent B-cell 121 lymphomas; mantle cell lymphoma (MCL); and Hodgkin's lymphoma/T-cell lymphomas (HL/TCL). Indolent 122 lymphomas included follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and 123 Waldenstrom macroglobulinemia. T-cell lymphomas included peripheral T-cell lymphomas not otherwise specified 124 (NOS), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphomas, angioimmunoblastic T-cell lymphoma 125 (AITL), and acute T-cell leukemia/lymphoma (ATLL). Most recent anticancer treatment types (such as cytotoxic 126 chemotherapy, anti-CD20 monoclonal antibody therapy, or small molecule inhibitors), date of last treatment prior 127 to vaccination, and duration of treatment were also collected.

128

#### 129 Outcome Measures

130 The primary outcome was a positive anti-COVID spike protein antibody titer following the primary COVID

131 vaccination series. The primary series was defined as either 2 doses of the COVID mRNA vaccines or 1 dose of the

132 COVID adenovirus vaccine. Among patients who had anti-COVID spike protein antibody results, COVID-19 history

133 was collected and included the following (if available): type of COVID vaccine received and number of doses,

134 history of positive COVID infection, and therapies received for COVID treatment (if applicable).

135

136 Secondary outcomes included positive anti-COVID spike protein antibody titers in the following patient subgroups:

137 patients who received an additional primary shot; different lymphoma subtypes; patients who received anti-CD20

- 138 monoclonal antibody therapy within the previous 12 months; and patients who received active anticancer
- 139 treatment. The additional primary shot was defined as either an additional dose ("third dose") of the COVID mRNA
- 140 vaccine or an additional dose ("second dose") of the COVID adenovirus vaccine. Active anticancer treatment was

- defined as the receipt of any therapy intended to treat cancer that was administered within the six months prior to
- 142 initiating the primary COVID vaccination series.
- 143
- 144

#### 145 Statistical Analysis

- 146 Demographic and clinical characteristics were summarized using descriptive statistics such as percentiles, median,
- 147 and interquartile range (IQR) by the primary series and additional shot groups, respectively. Seropositivity rates
- 148 between demographic and clinical categories were compared using Fisher's exact test or Pearson's chi-squared
- 149 tests. Unadjusted and multivariable adjusted logistic regression models (UVA and MVA, respectively) using
- 150 variables with p<0.05 in the unadjusted model were then fitted and their odds ratios (OR) and confidence intervals
- 151 (CI) were computed. A two-sided p-value < 0.05 is considered for the statistical significance. All analyses were
- 152 performed using R (ver 4.1)
- 153

## 154 **Results**

#### 155 Patient demographics and comorbidities

156 Two-hundred forty-three patients were identified with baseline characteristics as shown in Table 1. Overall, the

- 157 study population was elderly at a median age of 67 (IQR 59-75) years old, 52% of patients were male, and 78% of
- 158 patients were white. The most frequent comorbidities were cardiovascular disease (44%) and former smoking
- 159 history (30%). Lymphoma subtypes in our cohort were: indolent lymphomas (30%), Burkitt's, DLBCL, PMBL
- 160 combined (23%), CLL/SLL (22%), and Hodgkin's and T-cell lymphomas (HL/TCL) combined (18%). Of patients who
- 161 completed their primary vaccination series, one-hundred twelve (46%) patients received an additional primary
- 162 shot as of November 30, 2021.
- 163
- 164 Testing for anti-COVID spike protein antibodies occurred at a median of 61 (IQR 29-98) days after completion of
- the primary vaccination series and at a median of 37 (IQR 21-56) days after an additional primary shot. Majority of

- patients received COVID mRNA vaccines, and we were able to confirm the specific type in 197 (81%) patients. Only
- 167 3 patients received the COVID adenovirus vaccine (Table 1).
- 168

#### 169 **Primary outcome**

- 170 One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing their
- 171 primary COVID vaccination series (Fig 1 and Table 2). There were 112 patients who received an additional primary
- 172 shot, but only 46 of these patients had anti-COVID spike antibody protein levels resulted at the time of data cut-

173 off. Of these 46 patients, 38 patients (83%) had anti-COVID spike protein antibodies after receiving this dose (Table

- 174 2). Among the 38 patients who were seropositive after the additional primary dose, 18 patients were seronegative
- 175 after their primary COVID vaccination series and seroconverted only after the additional primary shot of COVID
- 176 vaccine.
- 177

178 Figure 1. Serologic response against COVID spike protein after the primary series in the overall population.

179 Table 1. Baseline characteristics

| Patient characteristics   | Primary series<br>N=243<br>n(%)                                       | Additional primary shot<br>N=112<br>n(%)                          |
|---|---|---|
| Age, years, median (IQR)  | 67 (59-75)  | 67 (59-75)  |
| Male  | 127 (52)  | 59 (53)   |
| <b>Race</b><br>Asian<br>Black or African American<br>Hispanic or Latino<br>White<br>Other<br>Missing  | 4 (2)<br>11 (4)<br>23 (10)<br>189 (78)<br>11 (4)<br>5 (2)             | 0<br>3 (3)<br>6 (5)<br>98 (88)<br>3 (3)<br>2 (2)                  |
| Disease type<br>Burkitt's, DLBCL, PMBL<br>CLL/SLL<br>Hodgkin's lymphomas (HL)<br>Indolent lymphomas <sup>†</sup><br>Mantle cell lymphoma (MCL)<br>T-cell lymphomas (TCL) <sup>‡</sup><br>Other <sup>§</sup> | 56 (23)<br>55 (22)<br>20 (8)<br>72 (30)<br>12 (5)<br>24 (10)<br>4 (2) | 24 (21)<br>24 (21)<br>9 (8)<br>36 (32)<br>8 (7)<br>8 (7)<br>3 (3) |

| Comorbidities                       |          |         |
|-------------------------------------|----------|---------|
| Cardiovascular disease <sup>¶</sup> | 106 (44) | 49 (44) |
| COPD                                | 6 (3)    | 3 (3)   |
| Autoimmune disease <sup>††</sup>    | 27 (11)  | 13 (12) |
| Mild liver disease <sup>‡‡</sup>    | 6 (3)    | 2 (2)   |
| Diabetes                            | 38 (16)  | 19 (17) |
| Chronic kidney disease              | 10 (4)   | 7 (6)   |
| HIV/AIDS                            | 6 (3)    | 2 (2)   |
| Smoking history                     |          |         |
| Current smoker                      | 8 (3)    | 4 (4)   |
| Former smoker                       | 74 (30)  | 33 (30) |
| Vaccine received                    |          |         |
| Pfizer-BioNTech                     | 115 (47) | 66 (59) |
| Moderna                             | 79 (33)  | 41 (37) |
| Johnson&Johnson                     | 3 (1)    | 0       |
| Unknown                             | 46 (19)  | 5 (4)   |
|                                     |          |         |

<sup>†</sup>Includes follicular lymphomas, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom macroglobulinemia

<sup>‡</sup>Includes peripheral T-cell lymphomas not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphomas, angioimmunoblastic T-cell lymphoma (AITL), and acute T-cell leukemia/lymphoma (ATLL)

<sup>§</sup>Include monoclonal gammopathy of undetermined significance (MGUS), T-cell prolymphocytic leukemia (T-PLL), Essential thrombocytosis, and primary CNS lymphoma

<sup>¶</sup>Cardiovascular disease defined as coronary artery disease, hypertension, or cerebrovascular accident <sup>††</sup>Includes autoimmune diseases, rheumatological disorders, and connective tissue disease <sup>‡‡</sup>Mild liver disease defined as either chronic hepatitis or cirrhosis without portal hypertension

DLBCL=diffuse large B-cell lymphoma; PMBL=primary mediastinal B-cell lymphoma; COPD=chronic obstructive pulmonary disease; HIV/AIDS=human immunodeficiency virus/acquired immunodeficiency syndrome

#### 180

#### 181 Table 2. Results

| Seropositivity against COVID spike protein   | Primary series<br>n(%)    | Additional<br>primary shot <sup>†</sup><br>n(%) | p-value |
|--|---------------------------|---|---------|
| Overall population   | 158/243 (65)              | 38/46 (83)                                      | -       |
| <i>Timing of last anticancer treatment</i><br>Within the last 6 months<br>More than 6 months                       | 45/92 (49)<br>83/104 (80) | 20/24 (83)<br>9/13 (69)                         | <0.001* |
| Timing of anti-CD20 monoclonal antibody<br>Received anti-CD20 mAb in past 12 mo.<br>Received anti-CD20 mAb ≥12 mo. | 22/45 (49)<br>46/54 (85)  | 3/7 (43)<br>5/5 (100)                           | -       |
| <i>Disease type</i><br>Burkitt's, DLBCL, PMBL<br>CLL/SLL   | 42/56 (75)<br>28/55 (51)  | 10/10 (100)<br>11/12 (92)                       |         |

|            |  |   |   |   | _            |
|------------|--|---|---|---|--------------|
|            | HL/TCL <sup>‡</sup><br>Indolent lymphomas <sup>§</sup><br>MCL<br>Other <sup>¶</sup>  | 34/44 (77)<br>44/72 (61)<br>6/12 (50)<br>4/4 (100)  | 3/3 (100)<br>9/15 (60)<br>4/5 (80)<br>1/1 (100)   | 0.04**  |              |
|            | History of COVID infection   | 19/24 (79)  | 1/1 (100)   | -   |              |
| 182<br>183 | <sup>†</sup> In patients with resulted anti-COVID spike prot<br><sup>‡</sup> Includes peripheral T-cell lymphomas not other<br>(ALCL), cutaneous T-cell lymphomas, angioimmu<br>leukemia/lymphoma (ATLL)<br><sup>§</sup> Includes follicular lymphomas, marginal zone ly<br>Waldenstrom macroglobulinemia<br><sup>¶</sup> Include monoclonal gammopathy of undeterm<br>leukemia (T-PLL), Essential thrombocytosis, and<br>*UVA 0.3 (0.1, 0.5) p<0.001; MVA 0.3 (0.2, 0.5),<br>**UVA 2.3 (1, 5), p=0.04; MVA 2.9 (1.3, 6.6), p=0<br>mAb=monoclonal antibody; DLBCL=diffuse large<br>lymphoma; TCL=Crcell lymphomas; MCL=manth | ein antibody levels<br>rwise specified (NO<br>unoblastic T-cell lyn<br>ymphoma, lymphop<br>ined significance (N<br>primary CNS lymph<br>p<0.001<br>0.01<br>e B-cell lymphoma;<br>SLL=small lymphoma | S), anaplastic large<br>nphoma (AITL), an<br>lasmacytic lympho<br>1GUS), T-cell proly<br>noma<br>PMBL=primary me<br>ytic lymphoma; HL | e cell lymphoma<br>d acute T-cell<br>oma, and<br>mphocytic<br>ediastinal B-cell<br>=Hodgkin |              |
| 184        | There were 8 patients that were seronegative fol   | lowing the addition   | al primary shot. O  | f these 8 patients  | s, there was |
| 185        | 1 patient that was seropositive after the primary  | series but was sero   | negative after the  | additional prima  | ry shot.     |
| 186        | There were 7 patients that did not produce antib   | odies following bot   | h the primary vaco  | cination series and   | d additional |
| 187        | primary shot. Of these 7 patients, 5 (71%) were d  | iagnosed with an in   | idolent lymphoma  | , 1 (14%) with CLI  | L/SLL, and 1 |
| 188        | (14%) with MCL. At the time of vaccination, 4 of t   | hese 7 (57%) patier   | nts were receiving  | active anticancer   | treatment.   |
| 189        | Active anticancer treatment in these patients cor  | nsisted of 50% (2/4)  | BTK inhibitor mor   | notherapy, 25% (1   | L/4)         |
| 190        | rituximab with chemotherapy, and 25% (1/4) oth   | er therapy.   |   |   |              |
| 191<br>192 |  |   |   |   |              |

#### 193 Secondary outcomes

- 194 There were 45 patients who received an anti-CD20 monoclonal antibody-containing regimen in the last 12 months
- prior to vaccination, and 22 (49%) of these patients produced antibodies after the primary COVID vaccination
- series (Table 2). This rate was numerically lower than 85% (46/54) of those who developed antibodies and received

- 197 an anti-CD20 antibody more than 12 months prior to vaccination. There were 5 patients who received an
- additional primary shot, of which all (5/5, 100%) were seropositive.
- 199
- 200 There were differences observed in the ability to produce serology with the COVID vaccine amongst lymphoma
- 201 subtypes. Of 55 patients with CLL/SLL, 28 (51%) produced antibodies after the primary COVID vaccination series
- 202 (Table 2 and Fig 2). There were 12 patients who received an additional primary shot, of which 92% were
- 203 seropositive (Fig 3). There were 20 CLL/SLL patients receiving anticancer treatment at the time of vaccination, of
- which 7 (7/20, 35%) patients were seropositive after the primary series and 6 (6/7, 86%) after the additional
- primary shot (Table 3). The most common treatment type in these patients was monotherapy with a Bruton's
- tyrosine kinase (BTK) inhibitor, where 36% (4/11) of patients produced antibodies. In comparison, there were 35
- 207 CLL/SLL patients not receiving active anticancer treatment and had a numerically higher rate of seroconversion at
- 208 60% (21/35) following receipt of the primary COVID vaccine series. CLL/SLL patients were less likely to mount an
- antibody response to the COVID vaccine when compared to those with other types of lymphoma.
- 210
- 211 Figure 2. Serologic response against COVID spike protein after primary series by lymphoma diagnosis.
- Figure 3. Serologic response against COVID spike protein after additional primary shot by lymphoma diagnosis.
- 213 Table 3. Serologic response against COVID spike protein by active anticancer treatment

| Seropositive against COVID spike   |   |  | N=92 <sup>†</sup>           |   |  |
|--|---|--|-----------------------------|---|--|
| protein  | Burkitt's,<br>DLBCL, PMBL<br>n(%)                 | CLL/SLL<br>n(%)                        | HL/TCL <sup>‡</sup><br>n(%) | Indolent<br>lymphomas <sup>§</sup><br>n(%)  | MCL<br>n(%)                            |
| COVID vaccination history<br>Primary series<br>Additional primary shot   | 12/18 (67)<br>7/7 (100)                           | 7/20 (35)<br>6/7 (86)                  | 14/20 (70)<br>2/2 (100)     | 8/26 (32)<br>3/6 (50)                       | 2/6 (33)<br>2/2 (100)                  |
| Type of anticancer treatment in<br>past 6 mo.<br>Anti-CD20 mAb monotherapy<br>BTK inhibitor<br>Rituximab + chemotherapy<br>Rituximab + BTK inhibitor<br>Anti-CD20 mAb + venetoclax<br>CAR T-cell therapy | 4/4 (100)<br>1/1 (100)<br>4/8 (50)<br>-<br>-<br>- | -<br>4/11 (55)<br>-<br>0/1<br>0/2<br>- |                             | 4/11 (36)<br>0/2<br>2/5 (40)<br>-<br>-<br>- | 2/2 (100)<br>0/1<br>-<br>-<br>-<br>0/1 |

| Auto-HSCT                   | -        | -        | 1/4 (25) | -        | -   |
|-----------------------------|----------|----------|----------|----------|-----|
| Brentuximab vedotin + other | -        | -        | 6/7 (86) | -        | -   |
| PI3K inhibitor              | -        | 0/1      | -        | -        | -   |
| Clinical trial              | -        | 2/3 (67) | -        | -        | 0/2 |
| Other                       | 3/5 (60) | 1/2 (50) | 7/9 (78) | 2/8 (25) | -   |

<sup>†</sup>Note: 2 patients in "other" diagnostic category with T-cell prolymphocytic leukemia (T-PLL) and primary CNS lymphoma

<sup>‡</sup>Includes peripheral T-cell lymphomas not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphomas, angioimmunoblastic T-cell lymphoma (AITL), and acute T-cell leukemia/lymphoma (ATLL)

<sup>§</sup>Includes follicular lymphomas, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom macroglobulinemia

DLBCL=diffuse large B-cell lymphoma; PMBL=primary mediastinal B-cell lymphoma; CLL=chronic lymphocytic leukemia; SLL=small lymphocytic lymphoma; HL=Hodgkin lymphomas; TCL=T-cell lymphomas; MCL=mantle cell lymphoma; mAb=monoclonal antibody; BTK=Bruton's tyrosine kinase; CAR=chimeric antigen receptor; Auto-HSCT=autologous hematopoietic stem cell transplant; PI3K=phosphoinositide 3-kinase

214

215

| 216 | For patients with HL/TCL, 34 of 44 (77%) patients produced antibodies after the primary series and all patients   |
|-----|---|
| 217 | (3/3, 100%) after the additional primary shot (Table 2, Fig 2 and Fig 3). Of 20 HL/TCL patients who received      |
| 218 | anticancer treatment in the last 6 months, 70% (14/20) produced antibodies at a median titer of 120 AU/mL         |
| 219 | (reference >=15 AU/mL), with 7 patients having a robust response of antibody titers >400 AU/mL. On statistical    |
| 220 | analysis, HL/TCL patients were more likely to elicit an antibody response to the COVID vaccine when compared to   |
| 221 | those with other types of lymphoma, and this response was significant on UVA (OR 2.285, 95% CI (1.038, 5.028),    |
| 222 | p=0.04) and MVA (OR 2.889, 95% CI (1.260, 6.628), p=0.012) when active anticancer therapy, lymphoma diagnosis,    |
| 223 | and history of COVID infection were considered in the multivariate analysis.                                      |
| 224 |   |
| 225 | There were 24 patients who had a documented COVID infection. Of these 24 patients, there were 13 patients who     |
| 226 | had a positive COVID PCR test result prior to receiving the primary COVID vaccine series; 3 patients had positive |
| 227 | COVID PCR test results following completion of the primary series and serology testing; 1 patient had completed   |
| 228 | the primary vaccine series and had COVID infection prior to serology testing; and 6 patients that were            |
| 229 | indeterminable due an unknown date of COVID vaccination or COVID PCR test result. In these patients with          |
| 230 | documented COVID infection, 19 (19/24, 79%) patients were seropositive after the primary vaccination series       |

(Table 2). There were 2 patients who received convalescent plasma, 4 patients who received monoclonal antibody
 therapy, and 1 patient who received both convalescent plasma and monoclonal antibody treatment for COVID
 treatment.

234

## 235 **Discussion**

In this retrospective, single center study, lymphoma patients (65%) were capable of mounting a humoral response
to the primary COVID vaccination series. The majority of patients completed their primary series and additional
primary shot with the COVID mRNA vaccines. The ability to produce antibodies to the COVID vaccine appeared to
vary according to their lymphoma diagnosis and type of active anticancer treatment received in the past 6 months.

241 Failure to generate a competent humoral immune response against COVID is associated with an elevated risk of 242 infection and poorer prognosis. Among all patients with hematological malignancies, those with B-cell 243 malignancies generally have suboptimal antibody responses following vaccination against COVID, ranging from 244 44%-79%, depending on the subtype. This is compared with seropositivity of 91%, 88%, and 95% in vaccinated 245 patients with AML, ALL, and MM, respectively [5]. Among the leukemias, CLL patients have the lowest rate of 246 seroconversion following vaccination, with 64% of patients failing to produce sufficient quantities of anti-spike 247 protein antibodies [5]. The low rate of seroconversion in patients with CLL was also observed in this study. 248 Approximately half (51%) of patients with CLL/SLL produced antibodies following their COVID vaccine, which was 249 considerably lower when compared to most subtypes of lymphoma. In contrast, patients with HL/TCL have been 250 shown to produce antibodies at higher rates 85%-98%, and this may be attributed to differences in disease biology 251 [5]. The results of this study showed patients with HL/TCL had significantly higher rates of seroconversion follow 252 the primary series at 77% compared to other lymphoma subtypes (UVA (OR 2.285, 95% CI (1.038, 5.028), p=0.04) 253 and MVA (OR 2.889, 95% CI (1.260, 6.628), p=0.012).

254

Seroconversion rates following vaccination are further reduced among patients receiving BTK inhibitors, anti-CD20
 monoclonal antibodies, or the BCL2 inhibitor venetoclax [5]. Bruton's tyrosine kinase is a cytoplasmic tyrosine

kinase responsible for B-cell maturation that is constitutively activated in CLL. The CD20 antigen is a pan-B cell
marker elevated in certain B-cell lymphomas. BCL2 is an anti-apoptotic protein expressed in high quantities in
cancer cells that inhibits the intrinsic pathway of apoptosis. Targeted therapy against these three markers have
proven to be effective therapeutic strategies against various B-cell malignancies by suppressing their functionality,
including the capacity to generate neutralizing antibodies. In our study, patients with CLL/SLL who received BTK
inhibitors with or without rituximab in the past 6 months had suboptimal antibody responses to the COVID
vaccine.

264

283

265 For patients receiving B-cell directed therapies, peripheral blood B-cell counts may begin to recover after 3 months 266 following treatment and may be completely reversed by 9 to 12 months [6]. A meta-analysis of thirty-eight studies 267 in patients treated with anti-CD20 monoclonal antibody therapy demonstrated that patients actively on these 268 therapies may have suboptimal antibody responses to all types of vaccines. This phenomenon was determined to 269 be at least partially ameliorated by 3-6 months following treatment, with repopulation of the B-cell pool in 12 270 months after treatment [8,9]. Similarly, patients in this study who received rituximab in the previous 12 months 271 had numerically lower seropositivity rates to the COVID vaccine compared to patients who had received rituximab 272 more than 12 months prior to vaccination. Of note, the majority of patients with Burkitt's, DLBCL or PMBL in this 273 study were not actively receiving anticancer therapy in the months prior to COVID vaccination and 75% were able 274 to mount a humoral response to vaccination. This suggests the ability of these patients to recover B-cell counts 275 following B-cell directed therapies and the need for optimal timing of vaccination following these therapies. 276 Furthermore, this adds to the complexity of predicting response to vaccines in patients with lymphoma. Not only is 277 it affected by the biology of the disease itself, but also the type of therapy they are receiving as well as its timing. 278 279 There are some limitations to this study. Firstly, this was a single-center, retrospective chart review. Some patients 280 received their COVID vaccine at an outside facility, therefore, the exact date and the type of vaccine received was 281 not consistently available. Secondly, the timing of the additional primary shot of COVID vaccine was not uniform 282 among all patients, and not all patients received this additional dose. As the COVID-19 pandemic progressed and

the Center for Disease Control updated recommendations based on available evidence, some patients received the

| 284  | additional primary shot of the COVID vaccine closer to the recommended 28 days after completion of the primary   |
|--|--|
| 285  | series than others, and some have yet to receive their additional primary shot. Lastly, although there were 243  |
| 286  | patients evaluated in the overall analysis, some subgroups of particular interest had smaller numbers of patients.   |
| 287  |  |
| 288  | In conclusion, lymphoma patients are capable of mounting a humoral response to the COVID mRNA vaccines.  |
| 289  | Although seroconversion is lower than in the normal population, it is still significant and warrants administration of   |
| 290  | COVID vaccine without delay, particularly during continuing high rate of infection. CLL/SLL appears predictive of a  |
| 291  | negative antibody response to the COVID vaccine, while HL/TCL histologies appeared to correlate to a positive  |
| 292  | antibody response, even with treatment within 6 months of vaccination. Our study suggests anti-CD20 monoclonal   |
| 293  | antibody therapy in the last 12 months may affect the ability to produce serology towards a COVID vaccine.   |
| 294  | Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical   |
| 295  | relevance in this patient population.  |
| 296  |  |
|  |  |
| 297  |  |
| 297<br>298<br>299  | Funding: The author(s) received no specific funding for this work.   |
| 297<br>298<br>299<br>300   | <b>Funding:</b> The author(s) received no specific funding for this work.<br><b>Data Availability:</b> The study involves a review of the electronic medical records of lymphoma patients who  |
| 297<br>298<br>299<br>300<br>301  | <ul> <li>Funding: The author(s) received no specific funding for this work.</li> <li>Data Availability: The study involves a review of the electronic medical records of lymphoma patients who received the COVID vaccine. The research data set has removed most, but not all protected health information (for</li> </ul>  |
| 297<br>298<br>299<br>300<br>301<br>302   | Funding: The author(s) received no specific funding for this work.         Data Availability: The study involves a review of the electronic medical records of lymphoma patients who         received the COVID vaccine. The research data set has removed most, but not all protected health information (for example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The   |
| 297<br>298<br>299<br>300<br>301<br>302<br>303  | Funding: The author(s) received no specific funding for this work.<br>Data Availability: The study involves a review of the electronic medical records of lymphoma patients who<br>received the COVID vaccine. The research data set has removed most, but not all protected health information (for<br>example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The<br>dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore,  |
| 297<br>298<br>299<br>300<br>301<br>302<br>303<br>303   | Funding: The author(s) received no specific funding for this work.<br>Data Availability: The study involves a review of the electronic medical records of lymphoma patients who<br>received the COVID vaccine. The research data set has removed most, but not all protected health information (for<br>example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The<br>dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore,<br>for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share  |
| 297<br>298<br>299<br>300<br>301<br>302<br>303<br>304<br>305                                    | Funding: The author(s) received no specific funding for this work.<br>Data Availability: The study involves a review of the electronic medical records of lymphoma patients who<br>received the COVID vaccine. The research data set has removed most, but not all protected health information (for<br>example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The<br>dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore,<br>for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share<br>portions of the data for appropriate review. Requests can be made through the corresponding author or directly to   |
| 297<br>298<br>299<br>300<br>301<br>302<br>303<br>304<br>305<br>306                             | Funding: The author(s) received no specific funding for this work.<br>Data Availability: The study involves a review of the electronic medical records of lymphoma patients who<br>received the COVID vaccine. The research data set has removed most, but not all protected health information (for<br>example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The<br>dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore,<br>for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share<br>portions of the data for appropriate review. Requests can be made through the corresponding author or directly to<br>representatives of Hackensack Meridian Health (Dr Andrew Ip; Email: Andrew.Ip@hmhn.org). |
| 297<br>298<br>299<br>300<br>301<br>302<br>303<br>304<br>305<br>306<br>307                      | Funding: The author(s) received no specific funding for this work.<br>Data Availability: The study involves a review of the electronic medical records of lymphoma patients who<br>received the COVID vaccine. The research data set has removed most, but not all protected health information (for<br>example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The<br>dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore,<br>for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share<br>portions of the data for appropriate review. Requests can be made through the corresponding author or directly to<br>representatives of Hackensack Meridian Health (Dr Andrew Ip; Email: Andrew.Ip@hmhn.org). |
| 297<br>298<br>299<br>300<br>301<br>302<br>303<br>304<br>305<br>306<br>307<br>308<br>309        | Funding: The author(s) received no specific funding for this work.<br>Data Availability: The study involves a review of the electronic medical records of lymphoma patients who<br>received the COVID vaccine. The research data set has removed most, but not all protected health information (for<br>example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The<br>dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore,<br>for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share<br>portions of the data for appropriate review. Requests can be made through the corresponding author or directly to<br>representatives of Hackensack Meridian Health (Dr Andrew Ip; Email: Andrew.Ip@hmhn.org). |
| 297<br>298<br>299<br>300<br>301<br>302<br>303<br>304<br>305<br>306<br>307<br>308<br>309<br>310 | Funding: The author(s) received no specific funding for this work.<br>Data Availability: The study involves a review of the electronic medical records of lymphoma patients who<br>received the COVID vaccine. The research data set has removed most, but not all protected health information (for<br>example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The<br>dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore,<br>for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share<br>portions of the data for appropriate review. Requests can be made through the corresponding author or directly to<br>representatives of Hackensack Meridian Health (Dr Andrew Ip; Email: Andrew.Ip@hmhn.org). |

## 312 **References**

- 313 1. Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-
- 314 CoV-2 in patients with haematological malignancies. Br J Haematol. 2021 Nov;195(3):371-377. doi:
- 315 10.1111/bjh.17704. Epub 2021 Jul 16. PMID: 34272724; PMCID: PMC8444788.
- 316 2. Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against
- COVID-19 Among Hospitalized Adults Aged ≥65 Years United States, January-March 2021. MMWR Morb
   Mortal Wkly Rep. 2021 May 7;70(18):674-679. doi: 10.15585/mmwr.mm7018e1. PMID: 33956782.
- 3. Haidar G, Mellors JW. Improving the Outcomes of Immunocompromised Patients With Coronavirus
- 320 Disease 2019. Clin Infect Dis. 2021 Sep 15;73(6):e1397-e1401. doi: 10.1093/cid/ciab397. PMID: 33949644;
- 321 PMCID: PMC8135839.
- 322 4. Xia A, Zhang Y, Xu J, et al. T Cell Dysfunction in Cancer Immunity and Immunotherapy. Front Immunol.

323 2019 Jul 19;10:1719. doi: 10.3389/fimmu.2019.01719. PMID: 31379886; PMCID: PMC6659036.

- 324 5. Greenberger LM, Saltzman LA, Senefeld JW, et al. Antibody response to SARS-CoV-2 vaccines in patients
- 325 with hematologic malignancies. *Cancer Cell*. 2021;39(8):1031-1033. doi:10.1016/j.ccell.2021.07.012
- 326 6. Ghione P, Gu JJ, Attwood K, et al. Impaired humoral responses to COVID-19 vaccination in patients with
- 327 lymphoma receiving B-cell-directed therapies. Blood. 2021 Sep 2;138(9):811-814. doi:
- 328 10.1182/blood.2021012443. PMID: 34189565; PMCID: PMC8245303.
- 329 7. Marchesi F, Pimpinelli F, Giannarelli D, et al. Impact of anti-CD20 monoclonal antibodies on serologic
   330 response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas. *Leukemia*. 2022;36(2):588-590.
- doi:10.1038/s41375-021-01418-8.
- 8. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week,
- open-label, phase I trial. Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363. Erratum in: Ann
  Neurol. 2008 Jun;63(6):803. Arnlod, Douglas [corrected to Arnold, Douglas]. PMID: 18383069.
- 335 9. Cho A, Bradley B, Kauffman R, et al. Robust memory responses against influenza vaccination in pemphigus
  336 patients previously treated with rituximab. *JCI Insight*. 2017;2(12):e93222. Published 2017 Jun 15.
- doi:10.1172/jci.insight.93222

## Figure 1. Serologic response against COVID spike protein after the primary series in the overall population



COVID Spike AB Testing Results After Primary COVID Vaccine Series in Different Types of Lymphomas

# Fig1

## Figure 2. Serologic response against COVID spike protein after primary series by lymphoma diagnosis

Covid Spike Antibody Result After Primary Series in Different Types of Lymphomas



# (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Figure 3. Serologic response against COVID spike protein after additional primary shot by lymphoma diagnosis

COVID Spike AB Testing Results After Additional Primary Shot in Different Types of Lymphomas

